Acadia Pharmaceuticals (ACAD) PT Raised to $20 at Morgan Stanley
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $21.43 +2.58%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $20.00 (from $19.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Nitto Denko (6988:JP) (NDEKY) PT Lowered to JPY3,400 at Nomura/Instinet
- Otsuka Holdings Co Ltd. (4578:JP) (OTSKY) PT Raised to JPY11,000 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
